HYD Pharma successfully completes research phase of new cancer drug

According to Hungarian news agency MTI, the company’s research and development division has produced a drug comprising deuterium-depleted water or DDW, which has potential to trim down the impact of chemotherapy and radiation including nausea, pain or hair loss.

During the research, tumor cells turned out to be highly sensitive to the extraction of deuterium (D).

The latest results also signify that deuterium can also influence other physiological processes such as glucose metabolism.

Further, the pharmaceutical firm will now move ahead with clinical trials, with its expenses expected to hit around a nine-figure range.

HYD Pharma has recently received $1.64m in funding from venture capital fund manager Primus Capital and it generated $2.8m in revenues last year.